Adoption of Global Quality Standards is required for Indian Pharma: OPPI

OPPI stands for the Organisation of Pharmaceutical Producers of India and it represents the research-based pharmaceutical companies in India. It completely engages with the government and other stakeholders to find the best sustainable healthcare solutions.

According to OPPI, Indian pharma required to adopt global quality standards to gain the growth of the sector and bring all stakeholders like regulators, industry, and governments to work jointly towards it.

WHO (World Health Organisation) has set some quality standards like GMP(Good Manufacturing Practices) and Indian pharma should need to maintain uniform baseline with them. Kanchana, OPPI director general said that the medicine making process should follow the global standards and need to implement from initial manufacturing stage to the delivery chain.

To address the quality issues in the pharmaceutical industry, all the government officials, industry representatives, industry associations and patient groups met in the Summit. All were discussed about the gamut of issues covering quality, ranging from labeling to packaging and storage at the summit.

Uttar Pradesh Department of Food Safety and Drug Administration study reports that around 38% of medicines are not effective as they are the outcome of low-quality standards. India has a number of pharmaceutical manufacturing industries but no quality standards maintained across the board.

To raise manufacturing quality standards, the government need to work with industry associations and other stakeholders including patient groups that represent the public and have to work together. That step will keep India globally competitive and Indian drugs sought after in global markets. Challenges like regulatory issues need to be addressed on the urgent basis for the growth of the Indian pharmaceutical industry.

Kanchana also commented on Government policies that policies should be more predictable and should remain for 3-5 years and Pharma Industry is in the need to have progressive policy changes.

OPPI just want to convey the importance of quality in delivering responsible and safe patient care as the quality of the medicine also plays an important role in cure process.

Related Posts

  • Pharma
  • July 3, 2025
  • 90 views
Cipla in talks to add new customers for its China factory, executive says

SHANGHAI – Indian drugmaker Cipla (CIPL.NS), opens new tab is looking to add at least two new overseas markets for its products manufactured in China, as the firm seeks to…

  • Pharma
  • July 3, 2025
  • 77 views
No link between COVID-19 vaccines & sudden deaths: ICMR-AIIMS Study

​Union Minister of Health and Family Welfare said that extensive studies by the Indian Council of Medical Research (ICMR) and All India Institute of Medical Sciences have conclusively established no…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Cipla in talks to add new customers for its China factory, executive says

Cipla in talks to add new customers for its China factory, executive says

No link between COVID-19 vaccines & sudden deaths: ICMR-AIIMS Study

No link between COVID-19 vaccines & sudden deaths: ICMR-AIIMS Study

Delhi High Court asks DGCI to decide on plea against licensing of weight-loss drugs

Delhi High Court asks DGCI to decide on plea against licensing of weight-loss drugs

Microplastics found in brain, ovaries, and placenta: Experts warn of silent threat to vital organs

Microplastics found in brain, ovaries, and placenta: Experts warn of silent threat to vital organs